Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospective stud...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Jeon, Young‐Woo, Yoon, Seugyun, Min, Gi June, Park, Sung‐Soo, Park, Silvia, Yoon, Jae‐Ho, Lee, Sung‐Eun, Cho, Byung‐Sik, Eom, Ki‐Seong, Kim, Yoo‐Jin, Kim, Hee‐Je, Lee, Seok, Min, Chang‐Ki, Lee, Jong Wook, Cho, Seok‐Goo
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853811/
https://ncbi.nlm.nih.gov/pubmed/31560165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars